Lupin gets USFDA nod for generic version of Clobex lotion
New Delhi: Drug maker Lupin said it has received approval from the US health regulator to market anti-inflammatory Clobetasol Propionate lotion in the American market.
The Mumbai-based firm said in a statement that it has received final approval for its product from the US Food and Drug Administration (USFDA).
The company's product is a generic version of Galderma Laboratories' Clobex Lotion, which is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
As per IMS MAT June data, Clobex had sales of USD 14.3 million in the US market.
American marketAnti InflammatoryaprrovalClobetasol Propionate lotionClobex lotioncorticosteroid-responsive dermatosesGalderma Laboratoriesgeneric versioninflammatoryLupinmarketpruritic manifestationsUSFDA
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd